DACA

DACA (XR 5000) is a blood-brain barrier-penetrating topoisomerase I and II inhibitor. DACA can be used in the research of colorectal cancer, leukemia and lung cancer[1][2][3][4].

Product Specifications

CAS Number

[89459-25-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/daca.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=CC2=CC3=CC=CC=C3N=C12)NCCN(C)C

Molecular Formula

C18H19N3O

Molecular Weight

293.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Padget K, et al. An investigation into the formation of N- [2- (dimethylamino) ethyl]acridine-4-carboxamide (DACA) and 6-[2- (dimethylamino) ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000;60 (6) :817-821.|[2]Dittrich C, et al. Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur J Cancer. 2003 Feb;39 (3) :330-4. |[3]Caponigro F, et al. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer. 2002 Jan;38 (1) :70-4. |[4]Twelves CJ, et al. Phase I and pharmacokinetic study of DACA (XR5000) : a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer. 1999 Aug;80 (11) :1786-91.